{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:07Z","timestamp":1792234507185,"version":"4.4.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL126903"],"award-info":[{"award-number":["R01 HL126903"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Steroidal mineralocorticoid-receptor-antagonists (MRAs), such as spironolactone and eplerenone, are guideline-directed therapies in patients with heart failure with reduced ejection fraction or resistant hypertension. However, the associated risk of hyperkalemia and hormonal side effects limit their broad use and downstream cardiorenal protection in high-risk patients with type 2 diabetes mellitus (T2DM) and moderate-to-advanced chronic kidney disease (CKD). The critical unmet need to improve long-term cardiorenal outcomes in such patients with CKD has sparked considerable efforts to the discovery and development of a new class of compounds. Finerenone is a novel, nonsteroidal MRA that has recently received regulatory approval with the indication of cardiorenal protection in patients with CKD associated with T2DM. Two landmark phase 3 clinical trials, FIDELIO-DKD and FIGARO-DKD, demonstrated that among patients with T2DM and a broad spectrum of CKD, finerenone reduced the risk of \u201chard\u201d cardiovascular and kidney failure outcomes as compared with placebo, with a minimal risk of hyperkalemia. Subgroup analyses of these trials also provided preliminary evidence that the efficacy and safety profile of finerenone was similar and irrespective of background therapy with other guideline-directed therapies, such as sodium-glucose co-transporter type 2 (SGLT-2) inhibitors and glucagone-like peptide 1 receptor agonists. Whether the combination of finerenone with a SGLT-2 inhibitor is more beneficial in patients with T2DM and CKD as compared with either therapy alone is a crucial research question that is currently under investigation in an ongoing clinical trial.<\/jats:p>","DOI":"10.1093\/ajh\/hpac124","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T10:10:36Z","timestamp":1667470236000},"page":"135-143","source":"Crossref","is-referenced-by-count":59,"title":["The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-2096","authenticated-orcid":false,"given":"Panagiotis I","family":"Georgianos","sequence":"first","affiliation":[{"name":"Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/hr.2016.137","article-title":"Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension","volume":"40","author":"Shibata","year":"2017","journal-title":"Hypertens Res"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid receptor antagonism in chronic kidney disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfz263","article-title":"Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population","volume":"36","author":"Wetmore","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"2023022409213983100_","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023022409213983100_","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonzalez-Blazquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction","volume":"67","author":"Gueret","year":"2016","journal-title":"Hypertension"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2013.00115","article-title":"PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy","volume":"4","author":"Orena","year":"2013","journal-title":"Front Pharmacol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"e0145666","DOI":"10.1371\/journal.pone.0145666","article-title":"Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628","volume":"10","author":"Ma","year":"2015","journal-title":"PLoS One"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (bay 94\u20138862) in individuals with mild or moderate hepatic impairment","volume":"44","author":"Heinig","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"e025079","DOI":"10.1161\/JAHA.121.025079","article-title":"Generalizability of FIGARO-DKD and FIDELIO-DKD trial criteria to the US population eligible for finerenone","volume":"11","author":"Chiu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.mayocp.2020.07.037","article-title":"Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database","volume":"96","author":"Folkerts","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10741-020-10039-9","article-title":"Serum potassium and heart failure: association, causation, and clinical implications","volume":"26","author":"Sfairopoulos","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"e002137","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023022409213983100_","author":"ClinicalTrials.gov."},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group.","year":"2020","journal-title":"Kidney Int"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/jpm12020223","article-title":"Evidence for cardiorenal protection with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetic kidney disease","volume":"12","author":"Georgianos","year":"2022","journal-title":"J Pers Med"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ekir.2022.01.1049","article-title":"Moderating effects in randomized trials-interpreting the P Value, confidence intervals, and hazard ratios","volume":"7","author":"Agarwal","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)","author":"Green","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2023022409213983100_","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpac124\/48417018\/hpac124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/36\/3\/135\/49326478\/hpac124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/36\/3\/135\/49326478\/hpac124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T21:23:59Z","timestamp":1678483439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/36\/3\/135\/6798912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,4]]},"published-print":{"date-parts":[[2023,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpac124","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,11,4]]}}}